Insights Type: Article

Biotech has never been an industry for the faint of heart, but the regulatory environment we are navigating today feels different. The forces shaping our industry, from policy upheaval and institutional erosion to a funding market that rewards the few and starves the many, are converging in ways that demand both attention and action.  About our Board … Read more

In Part 1, I explored the forces shaping biotech today—from clinical trial diversity and capital market shifts to global competition and regulatory uncertainty—while drawing insights from our recent Russo Partners Advisory Board Meeting. That discussion also underscored another set of challenges: drug pricing reform, public health appropriations, and the critical role of biotech leaders in … Read more

The biotech industry has long thrived at the intersection of science, policy, and capital markets, but that intersection today seems more like a collision, with forces pushing against each other in ways that demand urgent attention. At our recent Russo Partners Advisory Board meeting, industry leaders convened to discuss the critical issues shaping biotech today—from … Read more

In the world of biotech, effective communications are more than just a tool—it’s a lifeline. Early-stage biotech companies often face the daunting task of explaining complex science while vying for attention in a crowded market. Yet, it all begins with a clear and distinct message. Through our work at Russo Partners, we believe the key … Read more

In the world of biotech, communicating groundbreaking research has always been key to moving science forward. But let’s face it—while peer-reviewed journals and academic conferences are crucial, they tend to speak to a niche audience. The real magic happens when these discoveries break into the mainstream media. When The New York Times or The Wall … Read more